Stock 301126 HUNAN DAJIAWEIKANG PHARMACEUTICAL INDUSTRY CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd

Equities

301126

CNE1000054V3

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
10.57 CNY +5.81% Intraday chart for Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd +4.45% -18.88%
Apr. 22 Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 28 Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 119.999994 million in funding CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 4,686 3,075 2,691
Enterprise Value (EV) 1 4,691 4,042 4,615
P/E ratio 51.6 x 59.6 x 76.6 x
Yield 0.15% 0.19% 0.31%
Capitalization / Revenue 1.81 x 0.93 x 0.69 x
EV / Revenue 1.81 x 1.23 x 1.18 x
EV / EBITDA 33 x 31 x 28.9 x
EV / FCF -78.4 x -6.28 x 171 x
FCF Yield -1.27% -15.9% 0.59%
Price to Book 2.79 x 1.78 x 1.54 x
Nbr of stocks (in thousands) 206,506 206,506 206,506
Reference price 2 22.69 14.89 13.03
Announcement Date 4/24/22 4/21/23 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,189 2,457 2,340 2,592 3,292 3,904
EBITDA 1 147.2 163.1 133.1 142.1 130.4 159.7
EBIT 1 138.7 154 120.6 128.3 108.2 122.6
Operating Margin 6.34% 6.27% 5.15% 4.95% 3.29% 3.14%
Earnings before Tax (EBT) 1 108.8 119 90.13 96.01 76.17 48.55
Net income 1 77.99 87.65 64.85 68.26 51.12 34.3
Net margin 3.56% 3.57% 2.77% 2.63% 1.55% 0.88%
EPS 2 0.5200 0.5700 0.4187 0.4400 0.2500 0.1700
Free Cash Flow 1 -53.45 87.54 -186.2 -59.8 -644 27.05
FCF margin -2.44% 3.56% -7.96% -2.31% -19.56% 0.69%
FCF Conversion (EBITDA) - 53.67% - - - 16.94%
FCF Conversion (Net income) - 99.87% - - - 78.87%
Dividend per Share - - - 0.0340 0.0290 0.0400
Announcement Date 7/20/20 7/20/20 12/1/21 4/24/22 4/21/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 411 296 456 5.34 967 1,925
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.789 x 1.816 x 3.427 x 0.0376 x 7.421 x 12.05 x
Free Cash Flow 1 -53.4 87.5 -186 -59.8 -644 27.1
ROE (net income / shareholders' equity) 9.66% 9.52% 6.42% 5.02% 3.18% 2.11%
ROA (Net income/ Total Assets) 4.85% 4.9% 3.6% 3.1% 1.95% 1.66%
Assets 1 1,608 1,787 1,802 2,199 2,617 2,061
Book Value Per Share 2 5.760 6.310 6.730 8.130 8.340 8.460
Cash Flow per Share 2 0.3000 1.050 1.480 3.620 2.630 3.140
Capex 1 24.7 32.5 45.9 33.3 209 227
Capex / Sales 1.13% 1.32% 1.96% 1.28% 6.34% 5.81%
Announcement Date 7/20/20 7/20/20 12/1/21 4/24/22 4/21/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
HUNAN DAJIAWEIKANG PHARMACEUTICAL INDUSTRY CO.,LTD Stock Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
-18.88% 301M
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-4.44% 23.46B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+4.89% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+7.83% 8.35B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-21.35% 7.88B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+14.90% 5.21B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+10.84% 4.09B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.97% 4.11B
GALENICA AG Stock Galenica AG
-0.55% 3.87B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+20.72% 3.6B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 301126 Stock
  4. Financials Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd